JP2022541514A5 - - Google Patents
Info
- Publication number
- JP2022541514A5 JP2022541514A5 JP2022502902A JP2022502902A JP2022541514A5 JP 2022541514 A5 JP2022541514 A5 JP 2022541514A5 JP 2022502902 A JP2022502902 A JP 2022502902A JP 2022502902 A JP2022502902 A JP 2022502902A JP 2022541514 A5 JP2022541514 A5 JP 2022541514A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- solvate
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875409P | 2019-07-17 | 2019-07-17 | |
| US62/875,409 | 2019-07-17 | ||
| PCT/IB2020/000668 WO2021009567A1 (en) | 2019-07-17 | 2020-07-16 | Nlrp3 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022541514A JP2022541514A (ja) | 2022-09-26 |
| JP2022541514A5 true JP2022541514A5 (enExample) | 2023-07-06 |
| JP7595642B2 JP7595642B2 (ja) | 2024-12-06 |
Family
ID=72659815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502902A Active JP7595642B2 (ja) | 2019-07-17 | 2020-07-16 | Ｎｌｒｐ３モジュレーター |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12351564B2 (enExample) |
| EP (1) | EP3999179B1 (enExample) |
| JP (1) | JP7595642B2 (enExample) |
| KR (1) | KR102852270B1 (enExample) |
| CN (1) | CN114555569B (enExample) |
| AU (1) | AU2020314186B2 (enExample) |
| BR (1) | BR112022000855A2 (enExample) |
| CA (1) | CA3147571A1 (enExample) |
| IL (1) | IL289890B2 (enExample) |
| MX (1) | MX2022000712A (enExample) |
| WO (1) | WO2021009567A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020312800B2 (en) | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| WO2021009567A1 (en) | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CA3175729A1 (en) | 2020-03-16 | 2021-09-23 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| JP2024529839A (ja) * | 2021-06-29 | 2024-08-14 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
| KR102877100B1 (ko) | 2022-05-30 | 2025-10-24 | 주식회사 엘지에너지솔루션 | 배터리 진단 장치 및 방법 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
| WO2026054623A1 (ko) * | 2024-09-09 | 2026-03-12 | (주) 업테라 | 신규 nlrp3 억제제 화합물 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6929792B2 (ja) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| BR112018016671A2 (pt) | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| MA44729A (fr) | 2016-04-18 | 2021-05-12 | Novartis Ag | Composés et compositions pour traiter des états associés à une activité de nlrp |
| US11447460B2 (en) * | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| UA126675C2 (uk) | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| US11840543B2 (en) | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| CN110914256A (zh) | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| AU2018317800A1 (en) * | 2017-08-15 | 2020-02-13 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| TW201910317A (zh) * | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| ES2927851T3 (es) * | 2017-10-17 | 2022-11-11 | Novartis Ag | Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| US20230011652A1 (en) | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2021009567A1 (en) | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| AU2020312800B2 (en) | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| TWI894229B (zh) | 2020-03-16 | 2025-08-21 | 瑞士商諾華公司 | 作為yap/taz-tead蛋白-蛋白相互作用抑制劑之聯芳基衍生物 |
| CA3175729A1 (en) | 2020-03-16 | 2021-09-23 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CL2022002490A1 (es) | 2020-03-16 | 2023-05-05 | Novartis Ag | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead |
-
2020
- 2020-07-16 WO PCT/IB2020/000668 patent/WO2021009567A1/en not_active Ceased
- 2020-07-16 KR KR1020227005291A patent/KR102852270B1/ko active Active
- 2020-07-16 CN CN202080064393.6A patent/CN114555569B/zh active Active
- 2020-07-16 JP JP2022502902A patent/JP7595642B2/ja active Active
- 2020-07-16 US US17/627,084 patent/US12351564B2/en active Active
- 2020-07-16 CA CA3147571A patent/CA3147571A1/en active Pending
- 2020-07-16 IL IL289890A patent/IL289890B2/en unknown
- 2020-07-16 AU AU2020314186A patent/AU2020314186B2/en active Active
- 2020-07-16 MX MX2022000712A patent/MX2022000712A/es unknown
- 2020-07-16 BR BR112022000855A patent/BR112022000855A2/pt unknown
- 2020-07-16 EP EP20781062.3A patent/EP3999179B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022541254A5 (enExample) | ||
| JP2024529839A5 (enExample) | ||
| JP2025509697A5 (enExample) | ||
| JP2020514333A5 (enExample) | ||
| JP2023538408A5 (enExample) | ||
| JP6907173B2 (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP7145931B2 (ja) | 化合物の結晶多形、その製造方法及び用途 | |
| HRP20241656T1 (hr) | Derivat nitrila koji djeluje kao inhibitor dipeptidil peptidaze 1 i njegova upotreba | |
| JP7157804B2 (ja) | Ｎｌｒｐ活性に関連する病態を治療するためのスルホンアミド及びその組成物 | |
| JP2010501587A5 (enExample) | ||
| JP2017512186A5 (enExample) | ||
| JP2024516371A5 (enExample) | ||
| JP2023518044A5 (enExample) | ||
| JP2010539083A5 (enExample) | ||
| JP2016515096A (ja) | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 | |
| JP2021500403A5 (enExample) | ||
| CA2475712A1 (en) | Nicotinamide derivatives useful as pde4 inhibitors | |
| JP2004513882A5 (enExample) | ||
| JP2008543860A5 (enExample) | ||
| ME02188B (me) | Mali molekuli koji sadrže boron kao antiinflamatorni agensi | |
| JP2023504184A5 (enExample) | ||
| JP2022519696A5 (enExample) | ||
| JP2013525448A5 (enExample) | ||
| JP2023076632A5 (enExample) | ||
| JP2015508068A5 (enExample) |